1 / 12

Introduction

Metformin-mode of action and clinical implications for diabetes and cancer Nat Rev Endocrinol. 2014 Mar;10(3):143-56. The biguanide metformin has been used for its glucose-lowering effect since 1957 in Europe and since 1995 in the USA

ocean
Download Presentation

Introduction

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Metformin-mode of action and clinical implications for diabetes and cancerNat Rev Endocrinol. 2014 Mar;10(3):143-56.

  2. The biguanide metformin has been used for its glucose-lowering effect since 1957 in Europe and since 1995 in the USA • Yet despite being the most frequently prescribed antidiabetic treatment worldwide, its mechanism of action remains largely elusive • Pernicova et al. discuss the updated understanding of the molecular mechanisms through which metformin acts on metabolism, mainly focussing on liver gluconeogenesis, and on tumourigenesis • In addition, the potential implications of new discoveries about metformin molecular targets for the development of antidiabetic and anticancer therapies is also reviewed Introduction

  3. Metformin and diabetes mellitus • The glucose-lowering, insulin-sensitizing agent metformin works mainly by reducing gluconeogenesis and opposing glucagon-mediated signalling in the liver and, to a lesser extent, by increasing glucose uptake in skeletal muscle • The primary site of metformin action is the mitochondrion • The antihyperglycaemic effect of metformin is probably owing to defective protein kinase A signalling • Metformin affects lipid metabolism primarily via 5'-AMP-activated protein kinase (AMPK) activation

  4. Metformin and diabetes mellitus • Biguanides are recognized as indirect activators of AMPK • For about a decade, AMPK was the assumed prime mediator of metformin action • Metformin can activate AMPK by promoting AMP accumulation • However, reservations regarding the hypothesis of AMPK being the main driving force behind reduced hepatic gluconeogenesis have been accumulating over years, primarily owing to a lack of correlation between gluconeogenic gene expression and hepatic glucose output

  5. Metformin and diabetes mellitus • The AMPK model was seriously challenged when metformin lowered glucose production in the liver of transgenic mice that lacked AMPK or its upstream activator LKB1 • The proposed role of metformin in glucagon signalling (increased AMP reduces cAMP levels) has supported the AMPK‑independent antihyperglycaemic action of metformin • Nevertheless, a number of metformin effects are still attributed to AMPK

  6. Miller et al. suggested that metformin-induced changes in energy charge have contributory effects on gluconeogenesis, independent of cAMP and AMPK signalling The molecular targets of metformin include the mitochondrial complex I and other enzymes modulated by the altered energy charge, notably adenylate cyclase (inhibited by increased AMP levels), affecting glucagon signalling, and AMPK (stimulated by the increased AMP:ATP ratio) Metformin and diabetes mellitus

  7. Metformin and cancer • In 2005, a report associated metformin use with a reduced incidence of cancer, putting the drug into the cancer research spotlight • Diabetes mellitus has been associated with a 1.2–2.0-fold increase in cancer incidence • A report in 2010 suggested that metformin reduces this risk by approximately 40% compared with any other antidiabetic treatment • However, a population-based analysis has failed to show an association between improved survival and metformin use in diabetic patients with breast cancer aged >65 years

  8. Metformin and cancer • Mechanisms by which metformin attenuates tumourigenesis and has chemoprotective properties are not well-defined • An important limitation of many experimental studies is that metformin inhibits cell proliferation in vitro at supraphysiological concentrations, which are generally thought to be unachievable in patients • Moreover, many factors influence availability and response to metformin in tissue

  9. Metformin and cancer

  10. Future therapeutic directions • The AMP-binding P‑site on adenylate cyclase has been proposed as a new therapeutic target in insulin resistance and type 2 diabetes mellitus • Glucagon receptor is expressed in various tissues, and the cAMP–PKA pathway is involved in a plethora of signalling pathways, highlighting the need for a specific targeting strategy • Interaction of various pathways and drugs and their contribution to the pleiotropic effects attributed to metformin will probably remain a topic of debate in the future

  11. Conclusions • Metformin acts as a metabolic inhibitor and alters both whole-body and cellular energy metabolism • It is primarily used in patients with type 2 diabetes mellitus, and its main mechanism of action in this disease setting is inhibition of hepatic gluconeogenesis • Laboratory evidence of the antimitotic action of metformin is promising, although results from epidemiological studies remain controversial

  12. Conclusions • The combination of tumour genetics, patient metabolic profile and the cellular microenvironment determine the antitumour effect of metformin treatment • Many details of metformin action remain to be discovered, and the risk of harm must be considered when designing new metformin-based therapies • Hopefully, the knowledge gained from dissecting the pathways that metformin acts on will propel the development of multiple novel therapies

More Related